MGC Pharmaceuticals gained 11.9
The products included in the distribution deal cover MGC’s
MGC Managing Director Roby Zomer says the deal is exciting for the company and proves great validation for the extensive research and development for commercialisation.
“In tandem with our vertically integrated seed to pharma strategy we are building a truly international business that is setting the standards in the medical cannabis space,” he said.
MGC is European based and currently providing products to Europe, North America,
“This disease is a massive problem to society both financially and emotionally and currently we have no other pharmaceutical options,” he said.
HHI is Australian based and currently has distribution relationships across the UK and Australia for hospital pharmacies.
Cannvalate and MGC have also partnered for medicinal cannabis research in Melbourne to increase clinical support for cannabinoid pharmaceuticals.
Cannvalate’s cannabis network currently covers over 1,000 doctors and 600 pharmacies world wide, providing licensed producers immediate access to cannabis treatment products.
MGC’s market cap remains at $53.36 million as of this morning, trading shares at 4.7 cents a piece.